David Einhorn’s Talis Biomedical Corporation Common Stock TLIS Stock Holding History

David Einhorn’s Portfolio TLIS Stock Details TLIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	$1.11M	Hold	149,052	–	–	0.05%	36
2023 Q3	$860K	Hold	149,052	–	–	0.05%	34
2023 Q2	$1.07M	Hold	149,052	–	–	0.05%	35
2023 Q1	$1.1M	Hold	149,052	–	–	0.06%	34
2022 Q4	$996K	Hold	149,052	–	–	0.07%	32
2022 Q3	$1.52M	Hold	149,052	–	–	0.11%	32
2022 Q2	$1.82M	Hold	149,052	–	–	0.14%	37
2022 Q1	$3.15M	Buy	149,052 +44,432	+42%	+$1.54M	0.2%	36
2021 Q4	$6.29M	Buy	+104,620	New	+$7.83M	0.36%	32

Other funds holding TLIS

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Prelude Capital Management New York $1.37B AUM 71.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

David Einhorn's TLIS Position: Q4 2023 in Review

David Einhorn held its Talis Biomedical Corporation Common Stock (TLIS) position steady in Q4 2023 at 149,052 shares worth $1.11M. The position accounts for 0.05% of the portfolio, ranked #36.

David Einhorn first reported a position in TLIS in Q4 2021 and has held it in 9 quarters since. The position peaked at $6.29M in Q4 2021. 18 funds tracked by Wall St. Rank hold TLIS as of Q4 2023.

David Einhorn held 149,052 shares of Talis Biomedical Corporation Common Stock worth $1.11M as of Q4 2023.
David Einhorn left its Talis Biomedical Corporation Common Stock share count unchanged in Q4 2023.
Talis Biomedical Corporation Common Stock made up 0.05% of David Einhorn's portfolio in Q4 2023, its #36 holding.
David Einhorn first reported a position in Talis Biomedical Corporation Common Stock in Q4 2021 and has held it in 9 quarters since.
David Einhorn's Talis Biomedical Corporation Common Stock position peaked at $6.29M in Q4 2021.
18 funds tracked by Wall St. Rank held Talis Biomedical Corporation Common Stock as of Q4 2023.

Based on Greenlight Capital's 13F filing for Q4 2023, filed 14 Feb 2024.